We show that blocking immune checkpoints (PD1, LAG3), alone and in combination, can enhance effector T-cell responses in the tumor microenvironment of MM patients to a greater extent than by stimulating costimulatory molecules (OX40, GITR). The gene discussed is TNFRSF18; the disease is Miyoshi myopathy.